- Fall Senior Executive Conference
October 2, 2022 - October 4, 2022
5:00 pm - 12:30 pm EST
Please note that all times for our Fall Conference are Central European Time, and should show up correctly on your confirmation and iCal, but it does not show up correctly on our website calendar. We apologize for any confusion.
**This conference is for ALDA members only. If you are interested in attending and are a non-member, please consider your registration confirmation “in process.” A member of the ALDA team will reach out to you regarding membership and the necessary next steps.
The Fall Senior Executives Conference is one of our semi-annual meetings designed for member company C-suite executives, presidents and their senior executive teams. Each meeting focuses on emerging trends and business strategies and offers great insights and advice, along with many opportunities for dialogue with other senior executive attendees.
Past meetings have focused on proteomics, artificial intelligence, immunology, and digital and the transformation of healthcare. We include a global economic and financial outlook to complement each topical program. The 2022 Senior Executive Conference will focus on Trends in Pharma: The Latest Developments in Drug Discovery & Manufacturing.
ALDA Fall 2022 Senior Executive Conference
October 2-4, 2022
The Dolder Grand
For those in Zurich on Saturday, October 1:
ALDA Member-hosted Event (Optional)
Hosted by Tecan, Mettler-Toledo & Volpi
Location Enea in Rapperswil / Jona
All ALDA attendees and spouses are welcome to attend as part of their ALDA conference registration if you are in Zurich on Saturday!
Sunday, October 2:
6:00 – 9:00 PM CEST Opening Reception & Dinner with guest speaker
Member of German Council of Economic Experts
Peter Bofinger is one of Germany’s most distinguished economists. He is also one of the five ‘wise men’ – the name used to describe the members of the German Council of Economic Experts nominated by the federal government to evaluate economic developments – and a professor at the University of Würzburg.
Bofinger’s research focuses on international financial system reform and the euro crisis, new economic thinking and managed floating. He is a member of the scientific advisory board of the Austrian Institute of Economic Research, the Society of Economic and Social Sciences and chairs the Irving Fisher Society for Financial and Monetary Statistics.
Monday, October 3:
9:00 AM – 4:30 PM CEST
All topical content would take place on this day; the program runs from 9:00 am to 4:30pm
Pharma Market Overview: Developments in Europe, Asia & North America
Industry experts from McKinsey will set the stage for the day’s sessions, providing an overview of key developments and trends in the pharma space that have a direct impact on ALDA member companies, particularly as they relate to Europe and Asia.
Ralf Otto, Partner at McKinsey & Company and co-lead Biopharma service line and global Life Science Services group
Hemant Ahlawat, Senior Partner, McKinsey & Company
BioNTech–building a next generation Immunotherapy company
The rapid development of COVID vaccines was an unprecedented accomplishment. The mRNA technology at the heart of this accelerated timeline will continue to advance vaccine development in the years ahead. BioNTech—a true innovator in this space—will share the story of how these vaccines got us to where we are, and what it means in the years ahead for ALDA member companies and the world.
Dr. Holger Kissel, Vice President Business Alliances, BioNTech
How Proteomics is reshaping Drug Discovery in the Biopharma and CRO World
Proteomics—the focus of ALDA’s 2021 fall conference—continues to drive innovations in our space. Oliver Rinner with Biognosys will share the latest trends in how this crucial science is unlocking new opportunities in drug discovery.
Oliver Rinner, PhD, Chief Executive Officer, Biognosys AG
Financial Overview: The Impact of Developments in Pharma
Leaders from the JP Morgan Healthcare Investment Banking team will share their perspectives on the broader pharma market and what’s taking place with the key players in this space. What are the main areas of R&D anticipated in the coming years, and what have we seen recently that will have a lasting impact (mRNA, CGT developments, etc.)? They will also explore what these developments mean for our members/attendees, and how the tools market has been responding to these pharma developments, and the potential longer-term impacts on their products and services as it relates to the pharma end customer.
John Pissanos, Managing Director, Healthcare Investment Banking, J.P. Morgan
Kyle Finegan, Executive Director, Healthcare Investment Banking, J.P. Morgan
Panel: The Next Opportunities in Pharma
A panel of executives from dynamic pharm companies will share where they see their companies/processes heading and what types of tools/technology they need from our attendees in order to be successful down the road.
Alexander Beck, Head Operations Large Molecules & ATMP, Solvias AG
Yariv Hefez, Senior Vice President, Head Global Business Franchise Oncology at Healthcare Business, Merck Group
Tim Horlacher, Head of Research & Development, Bayer AG
Simon Sturge, Biotech Chair
Hermant Ahlawat, Senior Partner at McKinsey & Company
5:30 – 9:00 PM
Monday Night Reception & Dinner: Cruise on Lake Zurich
Tuesday, October 4:
8:00 – 9:30 AM CEST Closing Keynote
The Rt. Hon. Theresa May MP, Prime Minister of the United Kingdom (2016-2019)
Current Member of Parliament
11:30 AM – 12:30 PM
*NEW for Zurich* Optional Luncheon